In principle, mAbs represent an ideal therapeutic to treat these diseases, due to their high specificity for their protein targets [either directly targeting a toxic protein, or the processing enzymes responsible for its production, such as the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in Alzheimer's disease (AD)]. This evidence concerns the gene BACE1 and Alzheimer disease.